Directorate Change

8 June 2015

Imperial Innovations Group plc

Dr Robert Easton appointed as non-executive director

Imperial Innovations Group plc (AIM: IVO, "Innovations", the "Group") has announced the appointment of Dr Robert Easton to the Board as an independent non-executive director with effect from 1 August 2015, the start of the Group's new financial year.

Dr Robert Easton is a Partner and Managing Director at The Carlyle Group, the global alternative asset management company. He is a veteran of the firm and has performed multiple roles as an investment professional, including running the buyout team in the UK, serving as co-head of Carlyle Europe Technology Partners, a family of funds focussed on growth capital investments across the European technology sector and leading Carlyle's Ireland focussed fund. Across his 15 years at the firm, he has served on multiple portfolio company boards in many different sectors.

Prior to joining Carlyle in 2000, Dr Easton was Vice President of Corporate Development at Invensys plc. Dr Easton joined BTR in 1996 and was a key figure in the transformation of BTR from a diversified conglomerate to a focused engineering group and in the formation of Invensys from the merger of BTR and Siebe in 1999. During this period, he executed a total of 35 acquisitions and disposals with an aggregate value of €7 billion.

Dr Easton is a past Chairman of the British Venture Capital Association, a founding Director of the Walker Guidelines Monitoring Group for private equity disclosure, and at Imperial College he is a member of the Advisory Boards of the Business School and for the new Imperial West campus development. He has a first class honours degree in chemistry from Imperial College London and a Doctorate in organic synthesis from Oxford University.

Martin Knight, Chairman of Imperial Innovations, said:

"We are delighted that Robert has agreed to join the Board. He has an extensive business background encompassing private equity, corporations and investment banking, and a proven track record in executing high value transactions.

"During his time at Carlyle he has sat on many portfolio company boards, led different teams of investment professionals, and has developed expertise across a wide range of sectors in chemicals, advanced materials, renewables, engineering, software and ICT. He is a Chemistry graduate from Imperial College, has a doctorate from Oxford University and retains strong links with both institutions.

"We are looking forward to welcoming him to the Board. His scientific background and extensive track record of building technology businesses will be invaluable as we take our Group to the next level."

Dr Robert Easton, aged 52, is currently a limited partner in CECP Advisors LLP and is a director of the following companies:

· BRITISH HEART FOUNDATION

· CARLYLE ACQUISITIONS LIMITED

· CARLYLE (EUROPE) ACQUISITIONS LIMITED

· CARLYLE FINANCIAL INVESTMENTS LIMITED

· LILY O'BRIEN'S HOLDING LIMITED

· MIPLOB LIMITED

· ND1T LIMITED

· SADDELL LIMITED

· SEMERAL LIMITED

· SENSOR COATING SYSTEMS LIMITED

· SPORTS SUPPLEMENTS LTD

During the five year period up to the date of this announcement, Dr Easton has also served as a director of the following companies of which he is no longer a director:

· CECP INVESTMENT ADVISORS LIMITED

· ENSUS HOLDINGS LIMITED

· ENSUS LIMITED

· ENSUS MANAGEMENT SCHEME DM LIMITED

· ENSUS UK LIMITED

· LBI INTERNATIONAL N.V.

· PRACTICAL LAW GROUP LIMITED

· THE BRITISH PRIVATE EQUITY AND VENTURE CAPITAL ASSOCIATION

Dr Easton was a non-executive director of Ensus Limited, Ensus UK Limited and Ensus Holdings Limited from 2007 to 2013. In 2012 a refinancing of the Ensus group took place and the bank creditors of the Ensus group agreed to a debt for equity swap. Further information on the refinancing of the Ensus group is set out in the consolidated annual report and financial statements of Ensus Limited for the fifteen month period ended 31 March 2012.

Dr Easton holds no shares in Imperial Innovations Group plc

There are no other matters falling within Rule 17 and Schedule 2 paragraph (g) (iii) to (viii) of the AIM Rules to be disclosed

For further information contact: